Feature | January 31, 2012 | Helen Kuhl

The Impact of IMRT

Intensity-modulated radiation therapy is a complex but valuable treatment option.

Intensity modulated radiation therapy (IMRT) emerged as a new way to treat patients in the late 1990s and garnered attention because it offered the possibility to avoid radiating healthy tissue with more accuracy than conventional radiation therapy techniques. As a highly conformal 3-D therapy, its precise targeting of a tumor allows higher radiation doses to be delivered more safely. Since its inception, it has grown especially in use for cancers in the prostate, head and neck regions, as well as other areas of the body.

Its impact has been widespread. Radiation Medical Group in San Diego, Calif., says on its website that IMRT is “the single biggest improvement in radiation therapy in the last 30 years. It is very much like going from the propeller age to the jet age in aviation.” (www.rmg.md/IMRT.htm)

Varian, Accuray and Elekta are the primary vendors of linac technology to perform IMRT. Varian, Elekta, Philips and RaySearch offer treatment planning software, which is a critical part of the IMRT process. It is an involved and time-consuming process to create a treatment plan for IMRT and achieve the 3-D conformity. The International RadioSurgery Association (IRSA) estimates an IMRT treatment plan takes an average of two to three days per patient (www.irsa.org/imrt.html).

Because the IMRT process is complex and the doses are so high, there are more opportunities for error, so safety is a concern. In fact, the American Society for Radiation Oncology (ASTRO) kicked off a recent series of white papers addressing patient safety with “Safety Considerations for IMRT,” published in July 2011 in Practical Radiation Oncology. (www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)

“This report provides an opportunity to broadly address safe delivery of IMRT, with a primary focus on recommendations for human error prevention and methods to reduce the occurrence of errors or machine malfunctions that can lead to catastrophic failures or errors,” the report introduction said. The document includes tools and techniques to be used by clinics to ensure the safety of their IMRT programs.

Environmental and Technical Safety Concerns
The ASTRO white paper classifies safety hazards for IMRT into two groups: environmental and technical.

Environmental concerns are not unique to IMRT, but have safety implications for many other types of treatment. They include: lack of standard operating procedures, haste (i.e., inadequate time to perform all steps in a process), habituation, incomplete understanding or misuse of procedure/equipment, an inadequate QA program and lack of continuing staff education.

The technical concerns are areas such as inadequate commissioning of the clinical IMRT program, inadequate validation of the accuracy of treatment delivery parameters, improper use of one or more parts of the planning and delivery process, and inadequate investigation of discrepancies between treatment plan parameters and QA results. The white paper presents detailed recommendations and step-by-step guidelines to facilitate a safe IMRT program. (ASTRO also is in the process of developing two more white papers as part of its series, on peer review and image-guided radiation therapy. These can have an effect on IMRT practices as well.)

Customers Adopt New Technology
According to a report from KLAS, “Radiation Therapy 2011: A Dose of New Technology,” released last November, the oncology market in general has been growing. That trend is expected to continue, thanks to the need created by an aging population, and despite the slow economy and cuts in Medicare reimbursements.

“Providers are buying, and new vendors are entering the market,” KLAS said.

The report evaluated customer satisfaction with equipment and treatment planning software used for radiation therapy, including IMRT, as well as their concerns. It noted that radiation therapy providers are anxious to have the latest technology for treatment reasons, but also as a marketing tool. “The biggest provider draw is bleeding-edge technology, not only for patients’ benefit, but also for marketing and referrals,” the report stated.

Customers also are concerned with the safety of their systems, especially as patients read negative publicity about radiation dose. They believe their systems to be safe, but look for help with safety education from their vendors.

Reliability is another key factor for customers, who want a system with minimal downtime. “Providers are really looking for reliable equipment that is technologically advanced that they are able to draw referrals on. The combination of those attributes is driving satisfaction in the oncology market,” said the report.

For additional information, visit www.KLASresearch.com.

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init